Catégorie : Substances psychédéliques et therapeutique

Marginalisation, stigmatisation et abandon du LSD en médecine, Zoë Dubus, 2019

Marginalisation, stigmatisation et abandon du LSD en médecine Zoë Dubus Histoire, médecine et santé, 2019, 15, 87-105 Doi : 10.4000/hms.2168 https://journals.openedition.org/hms/2168 Abstracts Après avoir été l’une des substances pharmacologiques les plus étudiées des années 1950-1970, le LSD, puissant psychédélique ayant de nombreuses indications thérapeutiques, est abandonné par la communauté scientifique internationale au début des années 1970. Si des facteurs externes à la médecine ont eu un impact sur le déclin de ce médicament, il est également nécessaire de s’interroger sur les causes internes de ce rejet. Pour ce faire, une littérature anglo-saxonne émerge ces dernières années dans le champ des psychedelic studies, que nous enrichissons ici par une [...]

Lire la suite

How ecstasy and psilocybin are shaking up psychiatry, Paul Tullis, 2021

How ecstasy and psilocybin are shaking up psychiatry Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder. Paul Tullis https://www.nature.com/articles/d41586-021-00187-9?utm_source=twt_nnc&utm_medium=social&utm_campaign=naturenews&sf242359384=1 Nature, 2021,  589, 506-509 doi: 10.1038/d41586-021-00187-9   Illustration by Gizem Vural PDF version On a sunny day in London in 2015, Kirk Rutter rode the Tube to Hammersmith Hospital in hopes of finally putting an end to his depression. Rutter had lived with the condition off and on for years, but the burden had grown since the death of his mother in 2011, followed by a relationship break-up and a car accident the year [...]

Lire la suite

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing, L.S. Kaertner et al., 2021

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing, KAERTNER L.S., STEINBORN M.B., KETTNER H., SPRIGGS M.J., ROSEMAN L., BUCHBORN T., BALAET M., TIMMERMANN C., ERRITZOE D., CARHARDT-HARRIS R.L. : Nature, 2021, 11, 1941 Doi : 1038/s41598-021-81446-7   Abstract Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using a prospective (before, during and after) design. Individuals planning a weekly microdosing regimen completed surveys at strategic [...]

Lire la suite

Les nouveaux produits de synthèse, MILDECA, 2015

Les nouveaux produits de synthèse Publié le 10/08/2015 https://www.drogues.gouv.fr/comprendre/ce-qu-il-faut-savoir-sur/les-nouveaux-produits-de-synthese Les « nouveaux produits de synthèse » couramment appelés ainsi, portent officiellement le nom de « nouvelles substances psychoactives » (ONU et Union Européenne) car derrière cette appellation existent des substances psychoactives à la fois d’origine naturelle et synthétique. La plupart sont fabriquées en laboratoire, d’où leur appellation de « nouveaux produits de synthèse », voire, en anglais, de « research chemicals » (RC) ou de « designer drugs ». Certaines imitent les effets du cannabis, d’autres les effets de la cocaïne, de la MDMA / ecstasy ou des amphétamines. La première spécificité d’un certain nombre de ces substances est [...]

Lire la suite

Repeated Ketamine Infusions Linked to Rapid Relief of PTSD, Deborah Brauser, Medscape.com, 2021

Repeated Ketamine Infusions Linked to Rapid Relief of PTSD Deborah Brauser Medscape. com, January 18, 2021 Medscape Medical News © 2021 www.medscape.com/viewarticle/944282_print   Repeated intravenous infusions of ketamine provide rapid relief for patients with posttraumatic stress disorder (PTSD), new research suggests. In what investigators are calling the first randomized controlled trial of repeated ketamine administration for chronic PTSD, 30 patients received six infusions of ketamine or midazolam (used as a psychoactive placebo) over 2 consecutive weeks. Between baseline and week 2, those receiving ketamine showed significantly greater improvement than those receiving midazolam. Total scores on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) for the first group were almost 12 points [...]

Lire la suite

Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca, Nicole Leite Galvão-Coelho et al., 2020

Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca Nicole Leite Galvão-Coelho, Ana Cecília de Menezes Galvão, Raíssa Nóbrega de Almeida, Fernanda Palhano-Fontes, Isaac Campos Braga, Bruno Lobão Soares, João Paulo Maia-de-Oliveira, Daniel Perkins, Jerome Sarris and Draulio Barros de Araujo Journal of Psychopharmacology, 2020, 1-9. DOI : 10.1177/0269881120936486   Abstract Background : Ayahuasca is a traditional Amazon brew and its potential antidepressant properties have recently been explored in scientific settings. We conducted a double-blind placebo-controlled trial of ayahuasca with treatment-resistant depression patients (n = 28) and healthy controls (n = 45). Aims : We are evaluating the blood inflammatory biomarkers: C-reactive protein and [...]

Lire la suite

Reviewing the Potential of Psychedelics for the Treatment of PTSD, Erwin Krediet et al., 2020

Reviewing the Potential of Psychedelics for the Treatment of PTSD Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie, Eric Vermetten International Journal of Neuropsychopharmacology, 2020, 23, (6), 385–400 doi : 10.1093/ijnp/pyaa018 https://pubmed.ncbi.nlm.nih.gov/32170326/   Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not [...]

Lire la suite

PTSD as a mediator of the relationship between trauma and psychotic experiences, Daniela Strelchuk et al, 2020

PTSD as a mediator of the relationship between trauma and psychotic experiences Daniela Strelchuk, Gemma Hammerton, Nicola Wiles, Jazz Croft, Katrina Turner, Jonathan Heron and Stanley Zammit Psychological Medicine, 2020, 1–9. doi : 10.1017/S0033291720004821   Abstract Background : Traumatic experiences are associated with a higher risk of psychotic illnesses, but little is known about potentially modifiable mechanisms underlying this relationship. This study aims to examine whether post-traumatic stress disorder (PTSD) symptoms mediate the relationship between trauma and psychotic experiences (PEs). Methods : We used data from the Avon Longitudinal Study of Parents and Children to examine whether: PTSD symptoms mediate the relationships between (a) childhood trauma and [...]

Lire la suite

The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health, Sam Gandy et al, 2020

The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health Sam Gandy, Matthias Forstmann, Robin Lester Carhart-Harris, Christopher Timmermann, David Luke and Rosalind Watts Health Psychology Open, 2020, 1–21 Doi : 10.1177/2055102920978123   Abstract Therapeutic psychedelic administration and contact with nature have been associated with the same psychological mechanisms : decreased rumination and negative affect, enhanced psychological connectedness and mindfulness related capacities, and heightened states of awe and transcendent experiences, all processes linked to improvements in mental health amongst clinical and healthy populations. Nature-based settings can have inherently psychologically soothing properties which may complement all stages of psychedelic therapy (mainly [...]

Lire la suite